1. "2013"
Formats
  1. Journal Article (2495)
  2. Meeting Abstract (1292)
  3. Book Section (250)
  4. Conference Paper (18)
  5. Book Whole (17)
  6. Review (1)
Groups
  1. Department of Medicine (1421)
  2. GSK Faculty (1000)
  3. Surgery (873)
  4. Solid Tumor Oncology Division (781)
  5. Survivorship Research (671)
  6. Sloan Kettering Institute Faculty (646)

More Groups

People
  1. Jose Baselga (74)
  2. Clifford Hudis (69)
  3. Jedd Wolchok (65)
  4. Howard Scher (62)
  5. Mithat Gonen (62)
  6. Ross Levine (62)

More People

Years
  1. 2013 (4073)
Publications
  1. Journal of Clinical Oncology (366)
  2. Blood (190)
  3. Cancer Research (119)
  4. International Journal of Radiation Oncology, Biology, Physics (88)
  5. Modern Pathology (88)
  6. Laboratory Investigation (81)

More Publications

Publishers
  1. Elsevier Inc. (502)
  2. American Society of Clinical Oncology (386)
  3. Springer (304)
  4. Nature Publishing Group (249)
  5. Elsevier Science, Inc. (206)
  6. American Society of Hematology (192)

More Publishers

Results (4073)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Grisham, R. N.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Iyer, G.; Hyman, D. M.; Spriggs, D. R.; Aghajanian, C.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Evaluation of early response by anatomic imaging to predict survival among patients with group III rhabdomyosarcoma: A report from the Children's Oncology Group
    Meeting Abstract

    Hawkins, D. S.; Rosenberg, A. R.; Lyden, E.; Anderson, J. R.; Rodeberg, D. A.; Wolden, S. L.; Kao, S. C.; Parham, D.; Arndt, C. A. S.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial
    Meeting Abstract

    Heist, R. S.; Gandhi, L.; Shapiro, G.; Rizvi, N. A.; Burris, H. A.; Bendell, J. C.; Baselga, J.; Yerganian, S. B.; Hsu, K.; Ogden, J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET)
    Meeting Abstract

    Hobday, T. J.; Qin, R.; Moore, M. J.; Reidy, D. L.; Strosberg, J. R.; Kindler, H. L.; Shah, M. H.; Lenz, H. J.; Kaubisch, A.; Chen, H. X.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets)
    Meeting Abstract

    Harding, J. J.; Catalanotti, F.; Yaqubie, A.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Carvajal, R. D.; D'Angelo, S. P.; Dickson, M. A.; Schwartz, G. K.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Differential effects of bevacizumab on the risk of hand-foot syndrome associated with cytotoxic chemotherapy: An updated meta-analysis
    Meeting Abstract

    Gopal, A.; Flores, R. A.; Lacouture, M. E.; Wu, S.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Survey of palliative care patients WHO work
    Meeting Abstract

    Glare, P. A.; Alickaj, A.; Blinder, V. S.; Nikolova, T.; Ramirez, C.; Raghavan, V.; Crowley, J.; Frierson, E. L.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study
    Meeting Abstract

    Gonzalez-Angulo, A. M.; Juric, D.; Argilés, G.; Schellens, J. H. M.; Burris, H. A.; Berlin, J.; Middleton, M. R.; Schuler, M. H.; Van Geel, R.; Helgason, T.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic (ALL)
    Meeting Abstract

    Gore, L.; Zugmaier, G.; Handgretinger, R.; Locatelli, F.; Trippett, T. M.; Rheingold, S. R.; Bader, P.; Borkhardt, A.; Cooper, T. M.; O'Brien, M. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Retrospective analysis of risk factors for fatigue in clinical trial patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Gore, M. E.; Gruenwald, V.; Motzer, R. J.; Quinn, D. I.; Rini, B. I.; Lin, X.; Perkins, J. J.; Simantov, R.; Choueiri, T. K.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save